Modelling of compound combination effects and applications to efficacy and toxicity: State-of-the-art, challenges and perspectives

Drug Discovery Today

Volumn 21, Issue 2, 2016, Pages 225-238

  Bulusu, Krishna C ^a   Guha, Rajarshi ^b   Mason, Daniel J ^a   Lewis, Richard P I ^a   Muratov, Eugene ^c   Kalantar Motamedi, Yasaman ^a   Cokol, Murat ^d   Bender, Andreas ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c University of North Carolina   (United States)

^d SABANCI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; DRUG COMBINATION; RNA;

BIOLOGICAL ACTIVITY; COMPUTER MODEL; DRUG COMBINATION; DRUG EFFICACY; DRUG INTERACTION; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TOXICITY; GENE EXPRESSION; HUMAN; MOLECULAR MODEL; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; BIOLOGICAL MODEL; COMBINATION DRUG THERAPY; GENETICS;

ANIMALS; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GENE EXPRESSION; HUMANS; MODELS, BIOLOGICAL; RNA;

EID: 84968816746     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.09.003     Document Type: Review

References (134)

1. F. Li, and et al. Molecular-targeted agents combination therapy for cancer: developments and potentials Int. J. Cancer 134 2014 1257 1269
2. P.M. LoRusso, and et al. Accelerating cancer therapy development: the importance of combination strategies and collaboration Summary of an Institute of Medicine Workshop Clin. Cancer Res. 18 2012 6101 6109
3. P.D. Tamma, and et al. Combination therapy for treatment of infections with gram-negative bacteria Clin. Microbiol. Rev. 25 2012 450 470
4. K. Li, and et al. Multitarget drug discovery for tuberculosis and other infectious diseases J. Med. Chem. 57 2014 3126 3129
5. R.J. Worthington, and C. Melander Combination approaches to combat multidrug-resistant bacteria Trends Biotechnol. 31 2013 177 184
6. G.R. Zimmermann, and et al. Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discov. Today 12 2007 34 42
7. J.C. Dawson, and N.O. Carragher Quantitative phenotypic and pathway profiling guides rational drug combination strategies Front. Pharmacol. 5 2014 1 7
8. D.E. Bates, and R.J. Herman Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir Ann. Pharmacother. 40 2006 1190 1195
9. S.M. Sisodiya, and et al. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction Epilepsy Res. 48 2002 217 219
10. D.G. Bailey, and et al. Grapefruit juice-drug interactions Br. J. Clin. Pharmacol. 46 1998 101 110
11. H. Glaeser, and et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans Clin. Pharmacol. Ther. 81 2007 362 370
12. B. Prakash, and et al. Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up J. Ayurveda Integr. Med. 1 2010 215 218
13. W. Lam, and et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity Sci. Transl. Med. 2 2010 45 59
14. A.A. Izzo, and E. Ernst Interactions between herbal medicines and prescribed drugs: an updated systematic review Drugs 69 2009 1777 1798
15. S. Shi, and U. Klotz Drug interactions with herbal medicines Clin. Pharmacokinet. 51 2012 77 104
16. J. Jia, and et al. Mechanisms of drug combinations: interaction and network perspectives Nat. Rev. Drug Discov. 8 2009 111 128
17. B.H. Segal, and W.J. Steinbach Combination antifungals: an update Expert Rev. Anti. Infect. Ther. 5 2007 883 892
18. K. Yilancioglu, and et al. Target-independent prediction of drug synergies using only drug lipophilicity J. Chem. Inf. Model. 54 2014 2286 2293
19. C. Keith, and et al. Multicomponent therapeutics for networked systems Nat. Rev. Drug Discov. 4 2005 1 8
20. L.A. Mathews Griner, and et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells Proc. Natl. Acad. Sci. U. S. A. 111 2014 2349 2354
21. A.R. White, and et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent J. Antimicrob. Chemother. 53 Suppl. 1 2004 i3 i20
22. M.E. Steed, and et al. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations Antimicrob. Agents Chemother. 56 2012 5709 5714
23. K.A. Ryall, and A.C. Tan Systems biology approaches for advancing the discovery of effective drug combinations J. Cheminform. 7 2015 1 15
24. J. Lehár, and et al. Chemical combination effects predict connectivity in biological systems Mol. Syst. Biol. 3 2007 80
25. Y. Zhang, and et al. Computational analyses of synergism in small molecular network motifs PLoS Comput. Biol. 10 2014 e1003524
26. D.J. Huggins, and et al. Rational approaches to improving selectivity in drug design J. Med. Chem. 55 2012 1424 1444
27. C. Harrison Kinase inhibitors: analysing kinase inhibitor selectivity Nat. Rev. Drug Discov. 11 2012 21
28. M.S. Alavijeh, and et al. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery NeuroRx 2 2005 554 571
29. J. Lehár, and et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat. Biotechnol. 27 2009 659 666
30. F. Nosten, and N.J. White Artemisinin-based combination treatment of falciparum malaria Am. J. Trop. Med. Hyg. 77 2007 181 192
31. S. Ramón-García, and et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen Antimicrob. Agents Chemother. 55 2011 3861 3869
32. E. Ferrari, and et al. A lethal combination for cancer cells: synthetic lethality screenings for drug discovery Eur. J. Cancer 46 2010 2889 2895
33. S. Yuan, and et al. Effective elimination of cancer stem cells by a novel drug combination strategy Stem Cells 31 2013 23 34
34. J. Tang, and et al. Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways PLoS Comput. Biol. 9 2013 e1003226
35. M. Gerlinger, and et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 366 2012 883 892
36. M. Greaves, and C.C. Maley Clonal evolution in cancer Nature 481 2012 306 313
37. G. Jansen, and et al. Chemogenomic profiling predicts antifungal synergies Mol. Syst. Biol. 5 2009 338
38. J.A. Hill, and et al. Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations PLoS Genet. 9 2013 e1003390
39. L. Ejim, and et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy Nat. Chem. Biol. 7 2011 348 350
40. E. Basch, and et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial Lancet Oncol. 14 2013 1193 1199
41. A.H. Gradman, and et al. Combination therapy in hypertension J. Am. Soc. Hypertens. 4 2010 90 98
42. S.M. Patel, and L.D. Saravolatz Monotherapy versus combination therapy Med. Clin. North Am. 90 2006 1183 1195
43. D.S.H. Bell Combine and conquer: advantages and disadvantages of fixed-dose combination therapy Diabetes Obes. Metab. 15 2013 291 300
44. M. Cokol, and et al. Systematic exploration of synergistic drug pairs Mol. Syst. Biol. 7 2011 544
45. J.D. Feala, and et al. Systems approaches and algorithms for discovery of combinatorial therapies Wiley Interdiscip. Rev. Syst. Biol. Med. 2 2010 181 193
46. L. Nikolaeva, and A.S. Galabov In vitro inhibitory effects of dual combinations of picornavirus replication inhibitors Acta Virol. 43 1999 303 311
47. A.A. Borisy, and et al. Systematic discovery of multicomponent therapeutics Proc. Natl. Acad. Sci. U. S. A. 100 2003 7977 7982
48. P. Dragiev, and et al. Systematic error detection in experimental high-throughput screening BMC Bioinformatics 12 2011 25
49. G.S. Sittampalam, and et al. Assay Guidance Manual 2004 Eli Lilly Co. Natl. Cent. Adv. Transl. Sci.
50. B.T. Mott, and et al. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations Sci. Rep. 5 2015 11389 10.1038/srep13891
51. M.C. Berenbaum What is synergy? Pharmacol. Rev. 41 1989 93 141
52. C.I. Bliss The toxicity of poisons applied jointly-I Ann. Appl. Biol. 26 1939 585 615
53. S. Loewe The problem of synergism and antagonism of combined drugs Arzneimittelforschung 3 1953 285 290
54. T. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
55. N. Geary Understanding synergy Am. J. Physiol. Endocrinol. Metab. 304 2013 E237 E253
56. W.R. Greco, and et al. The search for synergy: a critical review from a response surface perspective Pharmacol. Rev. 47 1995 331 385
57. G.-S. Du, and et al. Cell-based drug combination screening with a microfluidic droplet array system Anal. Chem. 85 2013 6740 6747
58. D. An, and et al. Microfluidic system based high throughput drug screening system for curcumin/TRAIL combinational chemotherapy in human prostate cancer PC3 cells Biomol. Ther. (Seoul) 22 2014 355 362
59. P. Gerlee, and et al. Searching for synergies: matrix algebraic approaches for efficient pair screening PLoS ONE 8 2013 e68598
60. B.G. Small, and et al. Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing Nat. Chem. Biol. 7 2011 902 908
61. A.K. Chavali, and et al. Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease BMC Syst. Biol. 6 2012 27
62. X. Wan, and et al. Visualization of network target crosstalk optimizes drug synergism in myocardial ischemia PLoS ONE 9 2014 e88137
63. M.L. Miller, and et al. Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets Sci. Signal. 6 2013 ra85
64. M.B. Brandl, and et al. Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer Mol. Oncol. 8 2014 1548 1560
65. D. Murphy Gene expression studies using microarrays: principles, problems, and prospects Adv. Physiol. Educ. 26 2002 256 270
66. B. Verbist, and et al. Using transcriptomics to guide lead optimization in drug discovery projects: lessons learned from the QSTAR project Drug Discov. Today 20 2015 505 513
67. J. Zhao, and et al. Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs CPT pharmacometrics Syst. Pharmacol. 3 2014 e102
68. J.C. Costello, and et al. A community effort to assess and improve drug sensitivity prediction algorithms Nat. Biotechnol. 32 2014 1 103
69. G. Jin, and et al. An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data Bioinformatics 27 2011 i310 i316
70. D.M. Havaleshko, and et al. Prediction of drug combination chemosensitivity in human bladder cancer Mol. Cancer Ther. 6 2007 578 586
71. J. Kim, and et al. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy Bioinformatics 30 2014 2393 2398
72. L. He, and et al. TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples Bioinformatics 31 2015 1866 1868
73. J. Lamb, and et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science 313 2006 1929 1935
74. S.J. Dixon, and B.R. Stockwell Drug discovery: engineering drug combinations Nat. Chem. Biol. 6 2010 318 319
75. J. Lehár, and et al. Combination chemical genetics Nat. Chem. Biol. 4 2008 674 681
76. G. Giaever, and et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast Proc. Natl. Acad. Sci. U. S. A. 101 2004 793 798
77. D. Grimm, and M.A. Kay Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol. Ther. 15 2007 878 888
78. O. Sahin, and et al. Combinatorial RNAi for quantitative protein network analysis Proc. Natl. Acad. Sci. U. S. A. 104 2007 6579 6584
79. D. Grimm All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution Mol. Ther. 20 2012 1661 1663
80. D. Fazekas, and et al. SignaLink 2 - a signaling pathway resource with multi-layered regulatory networks BMC Syst. Biol. 7 2013 7
81. A.H. Tong, and et al. Systematic genetic analysis with ordered arrays of yeast deletion mutants Science 294 2001 2364 2368
82. C.L. Tucker, and S. Fields Lethal combinations Nat. Genet. 35 2003 204 205
83. A.H.Y. Tong, and et al. Global mapping of the yeast genetic interaction network Science 303 2004 808 813
84. A.B. Parsons, and et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways Nat. Biotechnol. 22 2004 62 69
85. P.Y. Lum, and et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes Cell 116 2004 121 137
86. P. Yeh, and R. Kishony Networks from drug-drug surfaces Mol. Syst. Biol. 3 2007 85
87. S. Vilar, and et al. Similarity-based modeling in large-scale prediction of drug-drug interactions Nat. Protoc. 9 2014 2147 2163
88. I. Cascorbi Drug interactions - principles, examples and clinical consequences Dtsch. Arztebl. Int. 109 2012 546 555
89. M. Sousa, and et al. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs J. Antimicrob. Chemother. 62 2008 872 878
90. B. Percha, and et al. Discovery and explanation of drug-drug interactions via text mining Pac. Symp. Biocomput. 29 2012 410 421
91. L. Tari, and et al. Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism Bioinformatics 26 2010 i547 i553
92. B. Percha, and R.B. Altman Informatics confronts drug-drug interactions Trends Pharmacol. Sci. 34 2013 178 184
93. M. Takarabe, and et al. Network-based analysis and characterization of adverse drug-drug interactions J. Chem. Inf. Model. 51 2011 2977 2985
94. J. Huang, and et al. Systematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction network PLoS Comput. Biol. 9 2013 e1002998
95. E.J. Guest, and et al. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models Br. J. Clin. Pharmacol. 71 2011 72 87
96. V.E. Kuz'min, and et al. Hierarchical QSAR technology based on the Simplex representation of molecular structure J. Comput. Aided Mol. Des. 22 2008 403 421
97. G.V. Kokurkina, and et al. Synthesis, antifungal activity and QSAR study of 2-arylhydroxynitroindoles Eur. J. Med. Chem. 46 2011 4374 4382
98. A.V. Zakharov, and et al. Quantitative prediction of antitarget interaction profiles for chemical compounds Chem. Res. Toxicol. 25 2012 2378 2385
99. E.N. Muratov, and et al. Existing and developing approaches for QSAR analysis of mixtures Mol. Inform. 31 2012 202 221
100. D.B. Searls Data integration: challenges for drug discovery Nat. Rev. Drug Discov. 4 2005 45 58
101. D.W. Young, and et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action Nat. Chem. Biol. 4 2008 59 68
102. A. Gaulton, and et al. ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 40 2012 1100 1107
103. A. Franceschini, and et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration Nucleic Acids Res. 41 2013 808 815
104. B.D. Lehmann, and J.A. Pietenpol Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes J. Pathol. 232 2014 142 150
105. M. Farr, and P. Bacon How and when should combination therapy be used? The role of an anchor drug Br. J. Rheumatol. 34 1995 100 103
106. M.W. Miller, and C.C. Church Arrhenius thermodynamics and birth defects: chemical teratogen synergy Untested, testable, and projected relevance Birth Defects Res. C. Embryo Today 99 2013 50 60
107. K.H. Banner, and N.J. Press Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease Br. J. Pharmacol. 157 2009 892 906
108. C. Haagsma, and et al. Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions Rheumatology 34 1995 104 108
109. T. Möttönen, and et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial FIN-RACo trial group Lancet 353 1999 1568 1573
110. R. Guthrie Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events Adv. Ther. 28 2011 473 482
111. Y.A. Kolesnikov, and et al. Topical methadone and meperidine analgesic synergy in the mouse Eur. J. Pharmacol. 638 2010 61 64
112. N. Berlow, and et al. An integrated approach to anti-cancer drug sensitivity prediction IEEE/ACM Trans. Comput. Biol. Bioinform. 11 2014 995 1008
113. D.J. Fall, and et al. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma J. Cancer 5 2014 720 727
114. L. Huang, and et al. DrugComboRanker: drug combination discovery based on target network analysis Bioinformatics 30 2014 i228 i236
115. G.E. Winter, and et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML Nat. Chem. Biol. 8 2012 905 912
116. K.-C. Hsu, and et al. Pathway-based screening strategy for multitarget inhibitors of diverse proteins in metabolic pathways PLoS Comput. Biol. 9 2013 e1003127
117. S.J. Sturla, and et al. Systems toxicology: from basic research to risk assessment Chem. Res. Toxicol. 27 2014 314 329
118. R.S.H. Yang, and et al. Chemical mixture toxicology: from descriptive to mechanistic, and going on to in silico toxicology Environ. Toxicol. Pharmacol. 18 2004 65 81
119. A.M. Lopez, and et al. A model-based approach for assessing in vivo combination therapy interactions Proc. Natl. Acad. Sci. U. S. A. 96 1999 13023 13028
120. C. Kelly, and et al. Two-stage model-free tests of synergy in drug combinations J. Biopharm. Stat. 22 2012 54 71
121. R. Tornero-Velez, and et al. Biogeographical analysis of chemical co-occurrence data to identify priorities for mixtures research Risk Anal. 32 2012 224 236
122. S. Ajmani, and et al. Characterization of mixtures. Part 1: Prediction of infinite-dilution activity coefficients using neural network-based QSPR models QSAR Comb. Sci. 27 2008 1346 1361
123. I. Oprisiu, and et al. QSPR approach to predict nonadditive properties of mixtures Application to bubble point temperatures of binary mixtures of liquids Mol. Inform. 31 2012 491 502
124. Y. Liu, and et al. DCDB: drug combination database Bioinformatics 26 2009 587 588
125. X. Chen, and et al. ASDCD: Antifungal Synergistic Drug Combination Database PLoS ONE 9 2014 e86499
126. F. Zhu, and et al. Update of TTD: Therapeutic Target Database Nucleic Acids Res. 38 2009 787 791
127. N.P. Tatonetti, and et al. Data-driven prediction of drug effects and interactions Sci. Transl. Med 4 2012 125ra31
128. P. Yeh, and et al. Functional classification of drugs by properties of their pairwise interactions Nat. Genet. 38 2006 489 494
129. V. Law, and et al. DrugBank 4.0: shedding new light on drug metabolism Nucleic Acids Res. 42 2014 D1091 D1097
130. M. Olah, and et al. WOMBAT: World of Molecular Bioactivity Chemoinform Drug Discov 2005 10.1002/3527603743.ch9
131. M. Kuhn, and et al. STITCH 4: integration of protein-chemical interactions with user data Nucleic Acids Res. 42 2014 401 407
132. T. Barrett, and et al. NCBI GEO: archive for functional genomics data sets - update Nucleic Acids Res. 41 2013 991 995
133. M. Kuhn, and et al. A side effect resource to capture phenotypic effects of drugs Mol. Syst. Biol. 6 2010 1 6
134. D.J. Dix, and et al. The toxcast program for prioritizing toxicity testing of environmental chemicals Toxicol. Sci. 95 2007 5 12